186 related articles for article (PubMed ID: 24560949)
21. DNA interactions of 2-pyrrolinodoxorubicin, a distinctively more potent daunosamine-modified analogue of doxorubicin.
Stepankova J; Studenovsky M; Malina J; Kasparkova J; Liskova B; Novakova O; Ulbrich K; Brabec V
Biochem Pharmacol; 2011 Aug; 82(3):227-35. PubMed ID: 21570955
[TBL] [Abstract][Full Text] [Related]
22. New insights into the mechanism of the DNA/doxorubicin interaction.
Pérez-Arnaiz C; Busto N; Leal JM; García B
J Phys Chem B; 2014 Feb; 118(5):1288-95. PubMed ID: 24417409
[TBL] [Abstract][Full Text] [Related]
23. Early stage intercalation of doxorubicin to DNA fragments observed in molecular dynamics binding simulations.
Lei H; Wang X; Wu C
J Mol Graph Model; 2012 Sep; 38():279-89. PubMed ID: 23079648
[TBL] [Abstract][Full Text] [Related]
24. Alginate/CaCO3 hybrid nanoparticles for efficient codelivery of antitumor gene and drug.
Zhao D; Liu CJ; Zhuo RX; Cheng SX
Mol Pharm; 2012 Oct; 9(10):2887-93. PubMed ID: 22894610
[TBL] [Abstract][Full Text] [Related]
25. Constructing transferrin receptor targeted drug delivery system by using doxorubicin hydrochloride and vanadocene dichloride.
Zhang Y; Xiang J; Liu Y; Zhang X; Tang Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5982-6. PubMed ID: 21862329
[TBL] [Abstract][Full Text] [Related]
26. The intercalation of DNA double helices with doxorubicin and nogalamycin.
Box VG
J Mol Graph Model; 2007 Jul; 26(1):14-9. PubMed ID: 17046298
[TBL] [Abstract][Full Text] [Related]
27. Molecular mechanism and binding free energy of doxorubicin intercalation in DNA.
Jawad B; Poudel L; Podgornik R; Steinmetz NF; Ching WY
Phys Chem Chem Phys; 2019 Feb; 21(7):3877-3893. PubMed ID: 30702122
[TBL] [Abstract][Full Text] [Related]
28. DOX-DNA Interactions on the Nanoscale: In Situ Studies Using Tip-Enhanced Raman Scattering.
Majzner K; Deckert-Gaudig T; Baranska M; Deckert V
Anal Chem; 2024 Jun; 96(22):8905-8913. PubMed ID: 38771097
[TBL] [Abstract][Full Text] [Related]
29. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
30. Anticancer activity of novel amino acid derivative of palladium complex with phendione ligand against of human colon cancer cell line.
Farhangian H; Eslami Moghadam M; Divsalar A; Rahiminezhad A
J Biol Inorg Chem; 2017 Oct; 22(7):1055-1064. PubMed ID: 28779308
[TBL] [Abstract][Full Text] [Related]
31. Fluorescence correlation spectroscopy for multiple-site equilibrium binding: a case of doxorubicin-DNA interaction.
Zhang X; Poniewierski A; Sozański K; Zhou Y; Brzozowska-Elliott A; Holyst R
Phys Chem Chem Phys; 2019 Jan; 21(3):1572-1577. PubMed ID: 30620015
[TBL] [Abstract][Full Text] [Related]
32. First Evidence of the Liposome-Mediated Deintercalation of Anticancer Drug Doxorubicin from the Drug-DNA Complex: A Spectroscopic Approach.
Das A; Adhikari C; Nayak D; Chakraborty A
Langmuir; 2016 Jan; 32(1):159-70. PubMed ID: 26605667
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles.
Hu FQ; Liu LN; Du YZ; Yuan H
Biomaterials; 2009 Dec; 30(36):6955-63. PubMed ID: 19782395
[TBL] [Abstract][Full Text] [Related]
34. The geometry of intercalation complex of antitumor mitoxantrone and ametantrone with DNA: molecular dynamics simulations.
Mazerski J; Martelli S; Borowski E
Acta Biochim Pol; 1998; 45(1):1-11. PubMed ID: 9701490
[TBL] [Abstract][Full Text] [Related]
35. Reduction-responsive disassemblable core-cross-linked micelles based on poly(ethylene glycol)-b-poly(N-2-hydroxypropyl methacrylamide)-lipoic acid conjugates for triggered intracellular anticancer drug release.
Wei R; Cheng L; Zheng M; Cheng R; Meng F; Deng C; Zhong Z
Biomacromolecules; 2012 Aug; 13(8):2429-38. PubMed ID: 22746534
[TBL] [Abstract][Full Text] [Related]
36. Structural characterization of the 1:1 adduct formed between the antitumor antibiotic hedamycin and the oligonucleotide duplex d(CACGTG)2 by 2D NMR spectroscopy.
Pavlopoulos S; Bicknell W; Craik DJ; Wickham G
Biochemistry; 1996 Jul; 35(29):9314-24. PubMed ID: 8755709
[TBL] [Abstract][Full Text] [Related]
37. Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity.
Duhem N; Danhier F; Pourcelle V; Schumers JM; Bertrand O; Leduff CS; Hoeppener S; Schubert US; Gohy JF; Marchand-Brynaert J; Préat V
Bioconjug Chem; 2014 Jan; 25(1):72-81. PubMed ID: 24328289
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous incorporations of two anticancer drugs into DNA. The structures of formaldehyde-cross-linked adducts of daunorubicin-d(CG(araC)GCG) and doxorubicin-d(CA(araC)GTG) complexes at high resolution.
Zhang H; Gao YG; van der Marel GA; van Boom JH; Wang AH
J Biol Chem; 1993 May; 268(14):10095-101. PubMed ID: 8486678
[TBL] [Abstract][Full Text] [Related]
39. Acenaphtho[1,2-b]pyrrole derivatives as new family of intercalators: various DNA binding geometry and interesting antitumor capacity.
Zhang Z; Yang Y; Zhang D; Wang Y; Qian X; Liu F
Bioorg Med Chem; 2006 Oct; 14(20):6962-70. PubMed ID: 16828559
[TBL] [Abstract][Full Text] [Related]
40. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.
Zhong Y; Yang W; Sun H; Cheng R; Meng F; Deng C; Zhong Z
Biomacromolecules; 2013 Oct; 14(10):3723-30. PubMed ID: 23998942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
